Biotech

Biotech By Adam Feuerstein

Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma

Biotech By Adam Feuerstein

Bluebird, troubled gene therapy maker, to lay off employees and reduce costs

Exclusive By Matthew Herper

Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments

Biotech By Jonathan Wosen

When a dire text message interrupted his talk, this doctor’s cancer research became painfully real

Biotech By Adam Feuerstein

The biotech scorecard for the second quarter: 21 stock-moving events to watch

Biotech By Megan Molteni

In the wake of big patent decision, it’s business as usual for CRISPR therapy developers

Biotech By Damian Garde

Vertex’s non-opioid painkiller meets goals in mid-stage studies

Biotech By Adam Feuerstein and Nicholas Florko

By narrow margin, FDA advisory panel concludes Amylyx ALS drug hasn’t proven effectiveness

Biotech By Adam Feuerstein and Nicholas Florko

Tracking the FDA advisory panel on Amylyx Pharma’s ALS treatment

Biotech By Adam Feuerstein

FDA review is critical of data on Amylyx ALS drug, but cites ‘regulatory flexibility’

In the Lab By Angus Chen

Scientists test common bacteria as a weapon to target pancreatic tumors

Biotech By Adam Feuerstein and Matthew Herper

Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics

Biotech By Kate Sheridan

What makes a biotech a biotech?

On Target By Angus Chen

After a dry spell for cancer immunotherapy, a new target offers a beacon of hope

Biotech By Jonathan Wosen

Illumina sues Guardant Health, saying former employees stole trade secrets to launch liquid biopsy firm

Biotech By Matthew Herper

Biogen publishes data on its Alzheimer’s drug in a little-known journal

Biotech By Jonathan Wosen

Armed with heaps of cash and a veteran team, an upstart looks to disrupt DNA sequencing

Biotech By Adam Feuerstein

Combination treatment from Nektar and Bristol Myers Squibb fails to benefit patients with melanoma, study shows

Biotech By Isabella Cueto

He was creating the building blocks for drug developers worldwide. Then Russia started to bomb Kyiv

Biotech By Adam Feuerstein

What to know about Amylyx’s ALS drug and a highly anticipated advisory panel meeting

Matt's Take By Matthew Herper

Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough

First Opinion By Adam Mossoff

The U.S. must fix its innovation engine: the patent system

Biotech By Adam Feuerstein

A key study of Gilead’s breast cancer drug meets goal, but withheld data raise doubts

Biotech By Adam Feuerstein

With cash running short, Bluebird Bio and its gene therapies face uncertain future

Biotech By Jonathan Wosen

‘Something is off here’: Black biotech entrepreneurs still struggle for funding as the industry pledges to diversify

Biotech By Adam Feuerstein and Damian Garde

With Aduhelm in limbo, Biogen starts laying off employees

Biotech By Damian Garde

Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study

Adam's Take By Adam Feuerstein

Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent

Biotech By Ryan Cross — The Boston Globe

Vesalius Therapeutics launches to develop treatments for common diseases